Innovative Digital PCR Stilla Technologies specializes in high-sensitivity, multiplex digital PCR solutions with a unique 6-color platform, making it highly attractive to research institutions, clinical labs, and biotech firms seeking precise genetic analysis for cancer, infectious diseases, or environmental testing.

Expansion Through Partnerships Strategic collaborations with companies like Source BioScience and integration with Niba Labs enhance product applications and market reach, presenting opportunities for sales teams to target diverse genomics and gene therapy sectors in the UK and beyond.

Recent Acquisition Backing The recent acquisition by Bio-Rad Laboratories for 8.49 billion dollars signals strong industry confidence and increased resources for growth, allowing sales teams to leverage the parent company's extensive distribution channels and customer base.

Growth Funding and Product Launches With $27 million in recent Series C funding and new assay launches, Stilla Technologies is expanding its product offerings and commercialization efforts, opening avenues for sales of supplementary assays and platform upgrades to existing customers.

Market Opportunities Target sectors include oncology, therapeutics, infectious disease research, and environmental testing, where high multiplexing and rapid, sensitive digital PCR solutions meet emerging industry demands, making the company a strategic partner for innovative life sciences solutions.